What does the first-line data for polatuzumab vedotin tell us about its role in R/R DLBCL?

During the 63rd ASH Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak with Gilles Salles, Memorial Sloane Kettering Cancer Center, New York, US. We asked, What does the first-line data for polatuzumab vedotin tell us about its role in R/R DLBCL?

Salles begins by reminding us of the POLARIX trial and discusses studies investigating further tools and combination therapies like POLARIS and POLARGO. Salles explains why moving polatuzumab vedotin to frontline therapy will mean it is less likely to be used for R/R patients. Finally, Salles highlights the advancements we have seen in the field and predicts further studies that will explore treatments utilizing therapies like bispecific antibodies.